AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31752976 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomicrobial S. maltophilia HAP
Number of subjects: 282
Study 31753019 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with anti-BTLA antibody
Number of subjects: 254
Study 31753019 — intervention group
Group type: COMPARATOR
Intervention: BTLA expression levels in cancerous tissues
Number of subjects: 254
Study 31753029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (15 mg/kg every 3 weeks for patients < 18 years; 1200 mg every 3 weeks for patients ≥ 18 years)
Number of subjects: 87
Study 31753029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 87
Study 31753466 — intervention group
Group type: EXPERIMENTAL
Intervention: Household air cleaners
Number of subjects: 0
Study 31753466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no household air cleaners)
Number of subjects: 0
Study 31753773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets (CRY BC-PLTs) transfusion
Number of subjects: 5
Study 31753773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets (CRY BC-PLTs)
Number of subjects: 5
Study 31753788 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program (10 weeks, intensity: 75-85% of heart rate reserve, frequency: 4 times/week, duration: 45 min)
Number of subjects: 35
Study 31753865 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 0
Study 31753876 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially adapted resistance training intervention
Number of subjects: 0
Study 31753876 — intervention group
Group type: EXPERIMENTAL
Intervention: Move It Or Lose It: community-based exercise intervention
Number of subjects: 0
Study 31753878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Peripheral Perfusion Index (PPI)
Number of subjects: 2300
Study 31754049 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 blockade
Number of subjects: 0
Study 31754316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 0
Study 31754316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31755936 — intervention group
Group type: EXPERIMENTAL
Intervention: PLHIV
Number of subjects: 200
Study 31755936 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 200
Study 31756197 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescription
Number of subjects: 20
Study 31756405 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity measured via dual-energy x-ray absorptiometry (DXA)
Number of subjects: 0
Study 31756720 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy for physical activity (PA)
Number of subjects: 114
Study 31756720 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent support for PA
Number of subjects: 114
Study 31757860 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary feeding (CF) initiated at <4 months
Number of subjects: 1013
Study 31757860 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary feeding (CF) initiated at ≥6 months
Number of subjects: 1013
Study 31757860 — intervention group
Group type: COMPARATOR
Intervention: Complementary feeding (CF) initiated at 4 to <6 months
Number of subjects: 1013
Study 31758304 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental resection (SR) for DIE
Number of subjects: 50
Study 31758430 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 506
Study 31758517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 31758517 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study 31758520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 159
Study 31758520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 31758682 — intervention group
Group type: EXPERIMENTAL
Intervention: DAAO method with phenylalanine intake of 15 mg · kg-1 · d-1 during early pregnancy
Number of subjects: 23
Study 31758682 — intervention group
Group type: EXPERIMENTAL
Intervention: DAAO method with phenylalanine intake of 21 mg · kg-1 · d-1 during late pregnancy
Number of subjects: 23
Study 31758682 — intervention group
Group type: EXPERIMENTAL
Intervention: IAAO method with phenylalanine intake of 21 mg · kg-1 · d-1 during late pregnancy
Number of subjects: 23
Study 31758682 — intervention group
Group type: COMPARATOR
Intervention: Previous adult male requirement
Number of subjects: 23
Study 31758773 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioCoach intervention (n=15)
Number of subjects: 25
Study 31758773 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (n=10)
Number of subjects: 25
Study 31759037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) placement
Number of subjects: 328
Study 31760599 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 210
Study 31760599 — intervention group
Group type: COMPARATOR
Intervention: Degludec
Number of subjects: 210
Study 31760711 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 3328
Study 31760711 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Number of subjects: 3328
Study 31760711 — intervention group
Group type: COMPARATOR
Intervention: No ACEI/ARB use
Number of subjects: 3328
Study 31760835 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 induction/consolidation
Number of subjects: 0
Study 31760835 — intervention group
Group type: COMPARATOR
Intervention: 7 + 3/5 + 2 chemotherapy
Number of subjects: 0
Study 31760881 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Satisfaction Questionnaire, 9 items (TSQM-9)
Number of subjects: 401
Study 31760881 — intervention group
Group type: EXPERIMENTAL
Intervention: Morisky Medication-Taking Adherence Scale (MMAS-4)
Number of subjects: 401
Study 31760881 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Illness Perception Questionnaire (B-IPQ)
Number of subjects: 401
Study 31760881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea score
Number of subjects: 401
Study 31761724 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived organoids (PDOs)
Number of subjects: 0
Study 31761724 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation (NACR)
Number of subjects: 0
Study 31761939 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese boys (zBMI > +2SD)
Number of subjects: 218
Study 31761939 — intervention group
Group type: COMPARATOR
Intervention: Control group (660 healthy boys, -2SD < zBMI ≤ +2SD)
Number of subjects: 218
Study 31761940 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 123
Study 31761940 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study 31761940 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D) with HbA1c > 8.5%
Number of subjects: 123
Study 31762387 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab additional Course 3
Number of subjects: 0
Study 31762387 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab additional Course 4
Number of subjects: 0
Study 31762387 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab additional Courses 3 and 4
Number of subjects: 0
Study 31763491 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-ingredient micronutrient supplement
Number of subjects: 135
Study 31763491 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 135
Study 31764446 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic Depression Assessment Scale (PDAS)
Number of subjects: 65
Study 31764446 — intervention group
Group type: COMPARATOR
Intervention: Presence of psychotic symptoms
Number of subjects: 65
Study 31764446 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic Depression Assessment Scale (PDAS) total score
Number of subjects: 65
Study 31764725 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 172
Study 31764725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 31764746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight (LMW) heparin plus aspirin (n=93)
Number of subjects: 187
Study 31764746 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (n=94)
Number of subjects: 187
Study 31764746 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary PlGF concentrations at mid-pregnancy (22-26 weeks of gestation)
Number of subjects: 187
Study 31765020 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Eikenella corrodens
Number of subjects: 0
Study 31765020 — intervention group
Group type: COMPARATOR
Intervention: Severe periodontitis with detection of 11 periodontal pathogens
Number of subjects: 0
Study 31765473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Seal® with erythritol air-polishing
Number of subjects: 96
Study 31765473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Seal® with polishing with brush and prophy paste (Cleanic®)
Number of subjects: 96
Study 31765473 — intervention group
Group type: EXPERIMENTAL
Intervention: Opal® Seal™ with erythritol air-polishing
Number of subjects: 96
Study 31765473 — intervention group
Group type: EXPERIMENTAL
Intervention: Opal® Seal™ with polishing with brush and prophy paste (Cleanic®)
Number of subjects: 96
Study 31765809 — intervention group
Group type: EXPERIMENTAL
Intervention: New Atrial Tachyarrhythmia (ATA)
Number of subjects: 1500
Study 31765809 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF)
Number of subjects: 1500
Study 31765809 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraventricular Tachycardia (SVT)
Number of subjects: 1500
Study 31766869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless THA with Delta ceramic bearings
Number of subjects: 76
Study 31766870 — intervention group
Group type: EXPERIMENTAL
Intervention: ThrombEmb group (patients with intraventricular thrombus or embolism)
Number of subjects: 1676
Study 31766870 — intervention group
Group type: EXPERIMENTAL
Intervention: ThrombEmb group
Number of subjects: 1676
Study 31766870 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on clinical parameters
Number of subjects: 1676
Study 31767018 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine stress (140 microg/kg/min infusion)
Number of subjects: 41
Study 31767018 — intervention group
Group type: COMPARATOR
Intervention: Rest (following intravenous contrast bolus 0.05 mmol/kg, gadobutrol)
Number of subjects: 41
Study 31767197 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol compliance
Number of subjects: 0
Study 31767463 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX-ID® intradermal injection technique
Number of subjects: 0
Study 31767533 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-accelerated partial breast irradiation (vAPBI) using single fraction of multicatheter interstitial high-dose rate brachytherapy (MIB) at a dose of 16 Gy.
Number of subjects: 26
Study 31767578 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms of genes related to vitamin D metabolism and transportation
Number of subjects: 18000
Study 31767579 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial colonisation of the proximal intestinal remnant identified using 16S rRNA sequence analysis and quantified using real-time PCR.
Number of subjects: 0
Study 31767583 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST) + laparoscopic cholecystectomy (LC)
Number of subjects: 2700
Study 31767583 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC)
Number of subjects: 2700
Study 31767583 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transcystic common bile duct exploration (LTCBDE) + laparoscopic cholecystectomy (LC)
Number of subjects: 2700
Study 31767586 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception women with RBC folate levels
Number of subjects: 8045
Study 31767586 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-pregnancy women with RBC folate levels
Number of subjects: 8045
Study 31767591 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent preoperative and intraoperative intervention including systematic information, preoperative screening, nutrient supplementation, physical exercise, medication review, blood management, carbohydrate loading, orientation aids, and geriatric anaesthesia concept
Number of subjects: 240
Study 31767591 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 240
Study 31768187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic network biomarkers (DNBs) of TCM syndromes
Number of subjects: 0
Study 31768187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine profiling and isobaric tags for relative and absolute quantitation (iTRAQ)
Number of subjects: 0
Study 31768261 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized follow-up through a smartphone application (app) on a weekly basis for one year.
Number of subjects: 113
Study 31768261 — intervention group
Group type: COMPARATOR
Intervention: Usual care including general advice regarding physical activity, exercise, and diet.
Number of subjects: 113
Study 31768262 — intervention group
Group type: EXPERIMENTAL
Intervention: 150,000 IU loading dose vitamin D
Number of subjects: 96
Study 31768262 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 96
Study 31768386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.i.d. (OCTAVE Induction 1)
Number of subjects: 101
Study 31768386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.i.d. (OCTAVE Sustain)
Number of subjects: 101
Study 31768386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.i.d. (OCTAVE Sustain)
Number of subjects: 101
Study 31768386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (OCTAVE Induction 1)
Number of subjects: 101
Study 31768386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (OCTAVE Sustain)
Number of subjects: 101
Study 31768930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function (measured by forced expiratory volume in the first second - FEV1)
Number of subjects: 520
Study 31768930 — intervention group
Group type: COMPARATOR
Intervention: Control group (COPD only patients)
Number of subjects: 520
Study 31769309 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 0
Study 31769793 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2838232 (20 mg) with cobicistat 150 mg
Number of subjects: 33
Study 31769793 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2838232 (50 mg) with cobicistat 150 mg
Number of subjects: 33
Study 31769793 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2838232 (100 mg) with cobicistat 150 mg
Number of subjects: 33
Study 31769793 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2838232 (200 mg) with cobicistat 150 mg
Number of subjects: 33
Study 31769793 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2838232 (≥50 mg) with cobicistat 150 mg
Number of subjects: 33
Study 31770380 — intervention group
Group type: EXPERIMENTAL
Intervention: ZJU index
Number of subjects: 107
Study 31770380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic steatosis index (HSI)
Number of subjects: 107
Study 31770380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid accumulation production index (LAPI)
Number of subjects: 107
Study 31770380 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adiposity index (VAI)
Number of subjects: 107
Study 31770437 — intervention group
Group type: EXPERIMENTAL
Intervention: BST-236 (aspacytarabine) administered intravenously once daily over 60 minutes for 6 consecutive days at doses ranging from 0.3 to 6 g/m2 per day.
Number of subjects: 26
Study 31770616 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype CC of rs1333049
Number of subjects: 933
Study 31770616 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 933
Study 31770616 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs3217992
Number of subjects: 933
Study 31771557 — intervention group
Group type: EXPERIMENTAL
Intervention: RISE (Recovering from IPV through Strengths and Empowerment) counseling intervention
Number of subjects: 23
Study 31771557 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from VHA providers
Number of subjects: 23
Study 31771600 — intervention group
Group type: EXPERIMENTAL
Intervention: iCycle training (FES cycling with virtual reality biofeedback)
Number of subjects: 11
Study 31771603 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention (Community Outreach and Patient Empowerment)
Number of subjects: 3053
Study 31771603 — intervention group
Group type: COMPARATOR
Intervention: Non-COPE participants (Control)
Number of subjects: 3053
Study 31771607 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term iron supplementation
Number of subjects: 0
Study 31771619 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation by EMS Winterthur
Number of subjects: 88
Study 31771619 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockable rhythm as first rhythm
Number of subjects: 88
Study 31771619 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 88
Study 31771619 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceased patients
Number of subjects: 88
Study 31771630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota composition in AS patients
Number of subjects: 150
Study 31771630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota composition in AS patients with increased fecal calprotectin (≥ 200 mg/kg, n=36)
Number of subjects: 150
Study 31771630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysbiosis in AS patients
Number of subjects: 150
Study 31771630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota composition in AS patients with normal fecal calprotectin (≤ 50 mg/kg, n=57)
Number of subjects: 150
Study 31771630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin levels
Number of subjects: 150
Study 31771630 — intervention group
Group type: COMPARATOR
Intervention: Comparison of fecal microbiota composition
Number of subjects: 150
Study 31771997 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography for estimating pulmonary artery pressures
Number of subjects: 97
Study 31771997 — intervention group
Group type: EXPERIMENTAL
Intervention: Assuming eRAP of 10 mmHg
Number of subjects: 97
Study 31771997 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of eRAP during exercise from resting eRAP
Number of subjects: 97
Study 31772104 — intervention group
Group type: EXPERIMENTAL
Intervention: Phthalate exposure in the NICU population
Number of subjects: 400
Study 31772104 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up from age 3 to 12 through ECHO programme
Number of subjects: 400
Study 31772121 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line HER2-targeted therapy, chemotherapy, and sequential endocrine therapy
Number of subjects: 977
Study 31772121 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tumor HR positivity (1%-9%)
Number of subjects: 977
Study 31772517 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed PCI
Number of subjects: 1072
Study 31772517 — intervention group
Group type: COMPARATOR
Intervention: Medication Therapy (MT)
Number of subjects: 1072
Study 31772517 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed PCI (after PSM)
Number of subjects: 1072
Study 31772517 — intervention group
Group type: COMPARATOR
Intervention: Medication Therapy (MT) (after PSM)
Number of subjects: 1072
Study 31772531 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchman device implantation during hybrid AF ablation
Number of subjects: 10
Study 31772605 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative continuation of statin therapy (CS group)
Number of subjects: 582
Study 31772605 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy (DS group)
Number of subjects: 582
Study 31772605 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking patients
Number of subjects: 582
Study 31772766 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal injection of ranibizumab after vitrectomy with ILM peeling
Number of subjects: 19
Study 31772984 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hyperthermia at 39°C to 43°C delivered using radiofrequency waves at 100 Mhz once a week after proton therapy.
Number of subjects: 2
Study 31772984 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton irradiation at a dose of 70 to 72 Gy delivered at 2.0 Gy per fraction daily for 7 weeks.
Number of subjects: 2
Study 31772984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of local hyperthermia and proton irradiation.
Number of subjects: 2
Study 31773324 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative IABP
Number of subjects: 181
Study 31773439 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and weekly paclitaxel therapy
Number of subjects: 251
Study 31773439 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CEC count
Number of subjects: 251
Study 31773439 — intervention group
Group type: EXPERIMENTAL
Intervention: CEC counts at 4 weeks
Number of subjects: 251
Study 31773794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-gastric bypass
Number of subjects: 120
Study 31773794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal transposition
Number of subjects: 120
Study 31773794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 120
Study 31773794 — intervention group
Group type: EXPERIMENTAL
Intervention: Transit bipartition
Number of subjects: 120
Study 31773794 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical groups (overall)
Number of subjects: 120
Study 31773794 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative β-cell function
Number of subjects: 120
Study 31773794 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial GLP-1 levels
Number of subjects: 120
Study 31773794 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 120
Study 31773973 — intervention group
Group type: EXPERIMENTAL
Intervention: LumiraDx INR Test
Number of subjects: 366